• Explore /
  • Poster
  • / Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.

Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.

Abstract Video & Slides Poster

Authors

null

Fabian Trillsch

AGO and Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany

Fabian Trillsch , Sven Mahner , Beyhan Ataseven , Rebecca Asher , Coraline Dubot , Andrew R. Clamp , Richard T. Penson , Amit M. Oza , Amnon Amit , Tomasz Huzarski , Antonio Casado , Giovanni Scambia , Michael Friedlander , Nicoletta Colombo , Keiichi Fujiwara , Gabe S. Sonke , Hannelore denys , Elizabeth S. Lowe , Eric Pujade-Lauraine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01874353

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6068)

DOI

10.1200/JCO.2020.38.15_suppl.6068

Abstract #

6068

Poster Bd #

239

Abstract Disclosures

Similar Posters

First Author: Philipp Harter

First Author: Sana Intidhar Labidi-Galy

First Author: Kathleen N. Moore

First Author: Stephanie L. Wethington